Applied Therapeutics (NASDAQ:APLT) Releases Quarterly Earnings Results

Applied Therapeutics (NASDAQ:APLT) announced its quarterly earnings data on Monday. The company reported ($0.24) earnings per share (EPS) for the quarter, Zacks reports.

Applied Therapeutics Price Performance

Shares of NASDAQ APLT traded down $0.00 on Monday, hitting $0.37. The company’s stock had a trading volume of 1,397,626 shares, compared to its average volume of 3,120,046. The stock has a 50 day moving average of $0.51 and a 200-day moving average of $3.29. Applied Therapeutics has a 12-month low of $0.30 and a 12-month high of $10.62. The company has a market capitalization of $42.94 million, a price-to-earnings ratio of -0.23 and a beta of 1.88.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on APLT shares. Royal Bank of Canada cut their price target on shares of Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating for the company in a report on Friday, December 20th. William Blair downgraded Applied Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, December 23rd. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.10.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.